Schlomo Staszewski

发表

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.

K. Tashima, D. Skiest, J. Stanford, 1999, The New England journal of medicine.

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients : a collaborative analysis of 18 HIV cohort studies

S. Cole, J. Sterne, R. Hogg, 2009 .

HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.

R Weber, A N Phillips, O Kirk, 2001, JAMA.

Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir Administered with Abacavir/Lamivudine Once Daily in Antiretroviral-Naïve HIV-1–Infected Adult Subjects

H. Stellbrink, S. Staszewski, A. Lazzarin, 2009, HIV clinical trials.

Virological response to protease inhibitor therapy in an HIV clinic cohort.

C. Sabin, A. Phillips, S. Staszewski, 1999, AIDS.

Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial.

D. H. Kennedy, D. Hawkins, M. Moroni, 1999, International journal of antimicrobial agents.

Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy.

C. Sabin, A. Phillips, S. Staszewski, 1999, AIDS.

Updated European Recommendations for the Clinical Use of HIV Drug Resistance Testing

JD Lundgren, N Clumeck, A. D. Luca, 2004, Antiviral therapy.

Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label study

A. Lazzarin, S. Esser, F. Mulcahy, 2011, European journal of medical research.

Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies

J. Sterne, A. d’Arminio Monforte, M. Egger, 2003, The Lancet.

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies

B. Ledergerber, F. Dabis, D. Costagliola, 2009, The Lancet.

Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.

C. Fox, L. Perrin, G. Pantaleo, 2000, The Journal of clinical investigation.

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.

S. Hammer, J. Montaner, D. Cooper, 2001, JAMA.

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies

Stephen R Cole, Jonathan A C Sterne, Ross Harris, 2009, The Lancet.

Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study.

S. Staszewski, V. Rickerts, H. Brodt, 2000, European journal of medical research.

Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure.

P. Harrigan, K. Hertogs, R. Pauwels, 1998, The Journal of infectious diseases.

A Family of Insertion Mutations between Codons 67 and 70 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Multinucleoside Analog Resistance

D. Stuart, D. Stammers, K. Hertogs, 1999, Antimicrobial Agents and Chemotherapy.

Clinical experience with non-nucleoside reverse transcriptase inhibitors.

J. Phair, S. Staszewski, C. Boucher, 1997, AIDS.

The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive individuals

S. Staszewski, M. Bickel, G. Ahlenstiel, 2010, European journal of medical research.

Fluconazole prophylaxis of recurrent oral candidiasis in HIV-positive patients

S. Staszewski, E. Helm, W. Stille, 1991, European Journal of Clinical Microbiology and Infectious Diseases.

Factors associated with viral rebound among highly treatment‐experienced HIV‐positive patients who have achieved viral suppression

S. Staszewski, M. Youle, C. Smith, 2009, HIV medicine.

Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America.

J. Sterne, O. Kirk, A. d’Arminio Monforte, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors

J. Condra, W. Schleif, A. Rhodes, 1993, Antimicrobial Agents and Chemotherapy.

Seroprevalence of HCV, HAV, HBV, HDV, HCMV and HIV in high risk groups/Frankfurt a.M., Germany.

S. Staszewski, H. Doerr, A. Berger, 1995, Zentralblatt fur Bakteriologie : international journal of medical microbiology.